NCT00912912View on ClinicalTrials.gov

Sunitinib Malate in Refractory Germ Cell Tumors

PHASE2TerminatedINTERVENTIONAL

Enrollment

5

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions

Genitourinary Disease

Interventions

DRUG

Sunitinib Malate

50 mg capsules once a day (by mouth) for 4 weeks in a row in a 6 week cycle.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Pfizer

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER